Literature DB >> 19783887

[A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].

Min Ki Shin1, Tae Hyo Kim, Kang Ju, Chang Yoon Ha, Hyun Ju Min, Woon Tae Jung, Ok Jae Lee.   

Abstract

Combination therapy of pegylated interferon alpha and ribavirin has been associated with various adverse effects, but sudden-onset hearing loss is uncommon. We report a 60-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon alpha and ribavirin for chronic hepatitis C. This patient had been diagnosed with chronic hepatitis C (genotype Ib) and early-stage liver cirrhosis 3 years previously, and had been treated with conventional interferon-alpha and ribavirin for 12 months. However, 6 months from the end of the treatment course the patient relapsed and received combination retreatment with pegylated interferon alpha-2b and ribavirin. He developed sudden-onset right-side hearing loss and tinnitus 42 weeks after the start of this retreatment. Pure-tone audiometry revealed a right-side hearing loss of 60 approximately 90 dB. The patient consequently immediately discontinued the pegylated interferon therapy and was given prednisone 60 mg/day for 10 days, after which the hearing loss had almost completely recovered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783887     DOI: 10.3350/kjhep.2009.15.3.370

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  2 in total

1.  Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.

Authors:  Savita Jain; Vandana Midha; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2011-09

Review 2.  A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.

Authors:  Christine Little; Maura K Cosetti
Journal:  Laryngoscope       Date:  2021-01-27       Impact factor: 2.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.